Hepatology

Meta-analysis results showed patients with ZZ AATD had a greater risk of liver disease and liver cancer than patients in comparator cohorts.

Past month binge drinking rates were greater among females 18-25 years of age than males from 2021-2023, reversing trends seen from 2017-2019.

The new global guideline consensus streamlines and simplifies existing MASLD recommendations from current guidelines and guidance documents.

Liver transplant recipients with infective endocarditis had greater odds of in-hospital mortality, ICU admission, and longer length of stay.

The new tablet formulation of maralixibat for the treatment of cholestatic pruritus in patients with ALGS and PFIC is expected to be available in June.

Phase 4 trial results showed switching to BSV after long-term TDF was noninferior for antiviral efficacy and led to improved kidney function and bone density.

An analysis of data from 2 PBC and PSC cohorts suggests fatigue is common, especially in females with PBC, and may be influenced by pruritus.

Scoping review results suggest AUD medications may improve hepatic outcomes in patients with ALD, but limited research exists on such an association.

Study findings suggest use and monitoring of commonly evaluated hepatic biomarkers and fibrosis scores may provide additional prognostic value in PBC.

Our Q1 recap for hepatology spotlights regulatory updates, clinical trial data, 2 new guidance documents, and the anniversary of a historic FDA approval.

PBC patients with increased serum IgG levels at initial evaluation experienced faster disease progression and a greater probability of liver-related death.

Bariatric surgery was associated with improved overall survival at an acceptable health care cost within a 10-year horizon.

The month in review spotlights coverage of the anniversary of resmetirom’s FDA approval and research in autoimmune hepatitis, HBV vaccination, and MASLD.

Mantzoros explains the need for multidisciplinary MASLD care and how to balance lifestyle modifications with emerging medications.

Kwo describes different barriers to hepatitis A and B vaccination for people with liver disease and looks ahead to future innovations and novel strategies.

Mantzoros explains factors contributing to the growing burden of MASLD and the need for collaboration between hepatology, primary care, and endocrinology.

Kwo explains why hepatitis A and B vaccination is important for people with liver disease and reviews different vaccine options.

Dara explains the importance of distinguishing DI-ALH from classic AIH, how their management differs, and where research in this field is heading.

Tabrizian discusses neoadjuvant immunotherapy for HCC, describing its success in the adjuvant setting but uncertainties about its use before transplant.

Dara describes similarities between drug-induced autoimmune-like hepatitis and idiopathic autoimmune hepatitis, as well as how to differentiate them.

Martinez explains the benefit of IBAT inhibitors for improving pruritus in children with Alagille syndrome and PFIC.

Goel describes the clinical impact of having 2 newly approved second-line PBC therapies and looks ahead to what’s next and where more research is needed.

Lammert describes the lack of developments in autoimmune hepatitis care over the past several decades and points to what might be next in disease management.

Positive topline results from PORTOLA show treatment with zetomipzomib resulted in steroid-sparing biochemical remissions in AIH.

Mitchell reviews FDA-approved drugs for reducing alcohol use, which ones can be used in patients with liver disease, and other therapies on the horizon.